uniQure N.V. (NASDAQ:QURE) participates in the field of gene therapy and has developed the first and currently the only gene therapy product to receive regulatory approval in the European Union. The company is developing a pipeline of adeno-associated virus (AAV)-based gene therapies both internally and through multiple collaborations. uniQure is initially focused on orphan diseases, but through multiple collaborations and the recent acquisition of the cardiology gene therapy company InoCard, has made the next step toward developing gene therapies targeting chronic and degenerative diseases that affect larger populations. For more information, visit the company’s website at www.uniQure.com